UNITED STATES SECURITIES AND EXCHANGE COMMISSION

~~SECURITIES AND EXCHANGE COMMISSION Washington~~WASHINGTON, D.C. 20549

FORM 8-K

~~CURRENT~~Current ~~REPORT~~Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~PURSUANT~~December 24, ~~TO SECTION 13 OR 15(d) OF~~2003 ~~THE SECURITIES EXCHANGE ACT OF 1934~~ Date of Report (Date of earliest event reported)~~: November 19, 2003~~

BioReliance Corporation ~~(Exact name of registrant as specified in charter)~~

~~Delaware~~ (~~State~~Exact orname ~~other~~of ~~jurisdiction~~Registrant ofas ~~incorporation~~specified in its charter)

0-22879		52-1541583
(Commission File Number)		(IRS Employer Identification No.)
14920 Broschart Road
Rockville, Maryland		20850
(Address of principal executive offices)		(Zip Code)

Commission File Number: 0-22879

~~Registrant’s~~Delaware ~~telephone~~(State ~~number,~~or ~~including~~other ~~area~~jurisdiction ~~code:~~of ~~(301~~incorporation or organization) ~~738~~ 52-~~1000~~ 1541583 (I.R.S. Employer Identification Number)

~~Not~~14920 ~~Applicable~~Broschart Road Rockville Maryland 20850 (~~Former~~Address ~~name~~of orprincipal ~~former~~executive ~~address,~~offices) if(Zip ~~changed~~Code) (Registrant’s ~~since~~telephone ~~last~~number, ~~report~~including area code): (301) 738-1000

Item 75. ~~Financial~~Other ~~Statements and Exhibits~~Events.

On December 24, 2003, BioReliance Corporation, a Delaware corporation (c“BioReliance”), announced that it had entered into an Agreement and Plan of Merger, dated as of December ~~Exhibits~~24, 2003, with Invitrogen Corporation, a Delaware corporation.

~~The~~BioReliance ~~following~~and ~~exhibit~~Invitrogen issued a joint press release dated December 24, 2003, which is ~~furnished~~filed ~~pursuant~~as toExhibit 99.1 ~~Item~~hereto and incorporated herein by reference, announcing the execution of the Agreement and Plan of Merger, which is filed as Exhibit 9:2.1 hereto and incorporated herein by reference.

99Item 7.1 ~~Report~~Financial ~~and~~Statements ~~Accounts of Q-One Biotech Group Limited for the year ended March 31, 2003, prepared in accordance with accounting principles generally accepted in the United Kingdom~~ and ~~expressed in U~~Exhibits.~~K. pounds Sterling.~~

Item 9. Regulation FD Disclosure


(c)	Number		Exhibit

		2.1	Agreement and Plan of Merger by and among Invitrogen Corporation, Baseball Acquisition Corporation and BioReliance Corporation, dated as of December 24, 2003.

		99.1	Joint Press Release issued by BioReliance Corporation and Invitrogen Corporation on December 24, 2003.

		99.2	Form of Voting and Tender Agreement by and among Invitrogen Corporation and certain stockholders of BioReliance Corporation.

~~As previously disclosed, BioReliance Corporation completed the acquisition of~~SIGNATURES ~~Q-One Biotech Group Limited, a privately-held company based in Glasgow,~~ ~~Scotland (“Q-One Biotech”), on September 23, 2003. Q-One Biotech’s Report and~~ ~~Accounts for the year ended March 31, 2003 are furnished as Exhibit 99.1 hereto.~~

~~SIGNATURE~~ Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~Pursuant~~BIORELIANCE toCORPORATION ~~the~~By: ~~requirements~~/s/ ofJohn ~~the~~L. ~~Securities~~Coker ~~Exchange~~John ~~Act~~L. ofCoker ~~1934,~~Senior ~~as amended~~Vice President, ~~the~~Finance ~~Registrant~~andAdministration ~~has~~and ~~caused~~Chief ~~this~~Financial ~~report to be signed on its behalf by the undersigned, thereunto duly authorized.~~ Officer

~~BIORELIANCE CORPORATION By~~Date: ~~/s/ John L. Coker John L. Coker Vice President~~January 5, ~~Finance and Administrative & Chief Financial Officer~~2004

~~Date: November 19, 2003~~EXHIBITS


Number		Exhibit

	2.1	Agreement and Plan of Merger by and among Invitrogen Corporation, Baseball Acquisition Corporation and BioReliance Corporation, dated as of December 24, 2003.

	99.1	Joint Press Release issued by BioReliance Corporation and Invitrogen Corporation on December 24, 2003.

	99.2	Form of Voting and Tender Agreement by and among Invitrogen Corporation and certain stockholders of BioReliance Corporation.

Filing Compare · BIORELIANCE CORP